[Sublingual buprenorphine tablets: initial clinical experiences in long-term therapy of cancer pain]. 1983

M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien

Buprenorphine sublingual tablets (0.2 mg) were investigated in therapy of cancer pain. In 67 patients there was a good analgetic effect in 60%, even in those cases treated with other opiates before. The induction time was quite long (60 min.) but is no problem in chronic administration. Effective pain relief was obtained even in final stages of cancer. The mean daily dose of buprenorphine had been 1.2-1.7 mg, the mean duration of analgesia being 6-8 hours with a single dose of 0.2-1.0 mg buprenorphine. Typical opiate-side-effects were registered and well tolerated after some days' treatment. There was no respiratory depression. Buprenorphine sublingual tablets are certainly a good alternative in orally available opioids.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009019 Morphinans Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS. Morphinan
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010148 Pain, Intractable Persistent pain that is refractory to some or all forms of treatment. Refractory Pain,Intractable Pain,Intractable Pains,Pain, Refractory,Pains, Intractable,Pains, Refractory,Refractory Pains
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
March 1988, Schmerz (Berlin, Germany),
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
June 1984, Anasthesie, Intensivtherapie, Notfallmedizin,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
March 1985, Acta anaesthesiologica Belgica,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
January 1979, British journal of clinical pharmacology,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
June 2020, Australian journal of general practice,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
January 1987, Zeitschrift fur Rheumatologie,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
June 2007, The Veterinary record,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
January 1998, Berliner und Munchener tierarztliche Wochenschrift,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
February 2011, P & T : a peer-reviewed journal for formulary management,
M Zenz, and S Piepenbrock, and M Tryba, and W Klauke, and M Everlien
January 2012, Indian journal of physiology and pharmacology,
Copied contents to your clipboard!